Dr. Reddy’s Laboratories announces the launch of Daptomycin for Injection, 500mg/vial single-dose vial in the U.S. Market

HYDERABAD, India & PRINCETON, N.J.–(BUSINESS WIRE)–Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY,
along with its subsidiaries together referred to as “Dr. Reddy’s”) today
announced the launch of Daptomycin for Injection, 500mg/vial single-dose
vial, a therapeutic equivalent generic version of Cubicin®
for Injection, approved by the U.S. Food and Drug Administration (USFDA).

The Cubicin® for Injection (daptomycin for injection) brand
and generic had U.S. sales of approximately $640.8 million MAT for the
most recent twelve months ending in March 2019 according to IQVIA
Health*.

Dr. Reddy’s Daptomycin for Injection is available in single-dose 15 ml
vials containing 500 mg of daptomycin.

Cubicin is a trademark of Merck Sharp & Dohme Corp.

*IQIA Retail and Non-Retail MAT March 2019

RDY-0519-246

About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124,
NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company,
committed to providing affordable and innovative medicines for healthier
lives. Through its three businesses – Pharmaceutical Services & Active
Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s
offers a portfolio of products and services including APIs, custom
pharmaceutical services, generics, biosimilars and differentiated
formulations. Our major therapeutic areas of focus are gastrointestinal,
cardiovascular, diabetology, oncology, pain management and dermatology.
Dr. Reddy’s operates in markets across the globe. Our major markets
include – USA, India, Russia & CIS countries, and Europe. For more
information, log on to: www.drreddys.com.

Disclaimer: This press release may include statements of future
expectations and other forward-looking statements that are based on the
management’s current views and assumptions and involve known or unknown
risks and uncertainties that could cause actual results, performance or
events to differ materially from those expressed or implied in such
statements. In addition to statements which are forward-looking by
reason of context, the words “may”, “will”, “should”, “expects”,
“plans”, “intends”, “anticipates”, “believes”, “estimates”, “predicts”,
“potential”, or “continue” and similar expressions identify
forward-looking statements. Actual results, performance or events may
differ materially from those in such statements due to without
limitation, (i) general economic conditions such as performance of
financial markets, credit defaults , currency exchange rates , interest
rates , persistency levels and frequency / severity of insured loss
events (ii) mortality and morbidity levels and trends, (iii) changing
levels of competition and general competitive factors, (iv) changes in
laws and regulations and in the policies of central banks and/or
governments, (v) the impact of acquisitions or reorganization ,
including related integration issues.

The company assumes no obligation to update any information contained
herein.

Contacts

INVESTOR RELATIONS
AMIT AGARWAL
amita@drreddys.com
(PH:
+91-40-49002135)

MEDIA RELATIONS
MITALI SARKAR
mitali.sarkar@drreddys.com
(PH:
+91-40- 49002121)